SartajMAroraMD

Gastroenterology • Covina, CA

Physician

Join to view full profile

Dr. Arora is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Arora's full profile

Already have an account?

Office
500 W San Bernardino Rd
Ste B
Covina, CA 91722
Phone+1 626-960-2326

Fax+1 626-960-9796
Is this information wrong?

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Gastroenterology, 2002 - 2005
Los Angeles County-Harbor-UCLA Medical CenterResidency, Internal Medicine, 1999 - 2002
University of California San Diego School of MedicineClass of 1999

Certifications & Licensure

CA State Medical License 2001 - 2024
American Board of Internal Medicine Gastroenterology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012-2013

Clinical Trials

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment Start of enrollment: 2015 Sep 22
Terminated
Phase 3
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) Start of enrollment: 2017 Jan 31
Active, not recruiting
Phase 3
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 Start of enrollment: 2018 Mar 21
Active, not recruiting
Phase 3
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy Start of enrollment: 2017 Nov 29
Completed
Phase 3
A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies Start of enrollment: 2017 Dec 07
Completed
Phase 3
An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) Start of enrollment: 2018 Jun 18
Active, not recruiting
Phase 3
Join now to see all

Other Languages

Spanish, Hindi, Punjabi

Hospital Affiliations

Emanate Health Inter-Community HospitalCovina, California
San Dimas Community HospitalSan Dimas, California
Emanate Health Foothill Presbyterian HospitalGlendora, California